Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 24 May 2024, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net Loss of Glenmark Pharmaceuticals reported to Rs 1218.28 crore in the quarter ended March 2024 as against net loss of Rs 428.30 crore during the previous quarter ended March 2023. Sales rose 1.95% to Rs 3016.01 crore in the quarter ended March 2024 as against Rs 2958.37 crore during the previous quarter ended March 2023.For the full year,net loss reported to Rs 1501.67 crore in the year ended March 2024 as against net profit of Rs 297.25 crore during the previous year ended March 2023. Sales rose 1.78% to Rs 11635.46 crore in the year ended March 2024 as against Rs 11431.94 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales3016.012958.37 2 11635.4611431.94 2 OPM %16.7213.45 -10.2714.30 - PBDT1128.95246.35 358 1519.361574.87 -4 PBT977.61111.34 778 937.451005.69 -7 NP-1218.28-428.30 -184 -1501.67297.25 PL Powered by Capital Market - Live News

Glenmark Specialty S.A. (Glenmark), a subsidiary of Glenmark Pharmaceuticals announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialize BeiGene`s oncology medicines, Tislelizumab and Zanubrutinib in India. Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for the treatment of advanced or metastatic esophageal squamous cell carcinoma and broad development for the treatment of various types of cancers, and Zanubrutinib is a BTK inhibitor approved for the treatment of certain hematological malignancies, with results of several studies reinforcing its favorable efficacy and safety profile. Under this strategic collaboration, Glenmark will be responsible for locally required development, registration and distribution providing access to BeiGene`s innovative oncology medicines for cancer patients across India. Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 May 2024Powered by Capital Market - Live News

Glenmark Pharmaceuticals (GPL) announced that for consumption and supply of renewable energy has entered into Securities Subscription &Shareholders�f Agreement with O2 Renewable Energy XXIV and O2 Energy SG PTE and Power Purchase Agreement with O2 Renewable Energy XXIV. In line with GPL`s commitment to become carbon neutral by 2030, this investment will enhance the share of renewable power in its operation. The acquisition of shares will enable GPL to invest in renewable energy and thereby comply with regulatory requirement for being a captive userunder Indian electricity laws. GPL will acquire minimum 26% stake on fully diluted basis in O2 Renewable Energy XXIV in order to qualify for captive requirements as per the provision of Electricity Act, 2003. Post�]acquisition, O2 Renewable Energy XXIV, will become an associate of GPL. Powered by Capital Market - Live News